Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE:002399)
China · Delayed Price · Currency is CNY 13.13
+0.06 (0.46%)
Sep 8, 2025, 3:04 PM CST
SHE:002399 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Net Income | 404.91 | 646.74 | -783.26 | 727.43 | 240.79 | 1,024 | Upgrade |
Depreciation & Amortization | 340.38 | 319.66 | 361.23 | 307.66 | 302.74 | 303.99 | Upgrade |
Other Amortization | 6.81 | 15.25 | 16.61 | 10.54 | 4.64 | 3.48 | Upgrade |
Loss (Gain) From Sale of Assets | -1.39 | 0.48 | 1.68 | 2.76 | 5.1 | -0.38 | Upgrade |
Asset Writedown & Restructuring Costs | 112.89 | 55.37 | 112.67 | 0.42 | 1.1 | 0.24 | Upgrade |
Loss (Gain) From Sale of Investments | 86.55 | -256.52 | 6.35 | 175.2 | 226.82 | -761.59 | Upgrade |
Loss (Gain) on Equity Investments | 141.82 | 141.82 | 447.95 | - | - | - | Upgrade |
Provision & Write-off of Bad Debts | 8.49 | - | - | 48.86 | 71.85 | 10.59 | Upgrade |
Other Operating Activities | 23.96 | 49.19 | -126.46 | 283.59 | 267.7 | 318.73 | Upgrade |
Change in Accounts Receivable | -152.33 | 105.66 | 316.89 | -176.1 | 141.77 | -346.75 | Upgrade |
Change in Inventory | 1,395 | 1,260 | 189.8 | -2,152 | -1,520 | -763.88 | Upgrade |
Change in Accounts Payable | -187.13 | -2.53 | -125.21 | 59.71 | 423.9 | 172.52 | Upgrade |
Change in Unearned Revenue | -100.91 | -100.91 | -68.29 | - | - | - | Upgrade |
Change in Other Net Operating Assets | -40.23 | -40.23 | 48.25 | -1.46 | -2.24 | -96.56 | Upgrade |
Operating Cash Flow | 1,948 | 2,194 | 398.22 | -756.61 | -6.63 | 37.28 | Upgrade |
Operating Cash Flow Growth | -12.87% | 450.99% | - | - | - | - | Upgrade |
Capital Expenditures | -193.23 | -199.62 | -437.43 | -222.42 | -193.86 | -212.49 | Upgrade |
Sale of Property, Plant & Equipment | 1.59 | 3.01 | 2.34 | 2.53 | 1.72 | 0.22 | Upgrade |
Sale (Purchase) of Intangibles | -3.15 | -3.15 | -7.45 | - | - | - | Upgrade |
Investment in Securities | -549.32 | -503.75 | 1,565 | 336.53 | 323.36 | -2,038 | Upgrade |
Other Investing Activities | -60.14 | 288.46 | 99.36 | 133.2 | 588.71 | 76.36 | Upgrade |
Investing Cash Flow | -804.25 | -415.05 | 1,222 | 249.84 | 719.93 | -2,174 | Upgrade |
Long-Term Debt Issued | - | 2,687 | 5,109 | 6,756 | 3,694 | 4,516 | Upgrade |
Long-Term Debt Repaid | - | -4,691 | -6,033 | -6,162 | -3,767 | -5,230 | Upgrade |
Net Debt Issued (Repaid) | -1,494 | -2,005 | -923.29 | 594.15 | -72.79 | -714.06 | Upgrade |
Issuance of Common Stock | - | - | - | - | - | 3,538 | Upgrade |
Common Dividends Paid | - | - | -176.21 | -251.01 | -412.48 | -447.48 | Upgrade |
Other Financing Activities | -121.02 | -135.09 | -110.68 | -13.58 | -15.81 | 129.72 | Upgrade |
Financing Cash Flow | -1,615 | -2,140 | -1,210 | 329.56 | -501.08 | 2,506 | Upgrade |
Foreign Exchange Rate Adjustments | 13.36 | 16.83 | 36.33 | 17.28 | -62.83 | -116.27 | Upgrade |
Net Cash Flow | -458.02 | -343.82 | 445.94 | -159.93 | 149.39 | 253.71 | Upgrade |
Free Cash Flow | 1,755 | 1,995 | -39.22 | -979.03 | -200.49 | -175.21 | Upgrade |
Free Cash Flow Growth | -4.59% | - | - | - | - | - | Upgrade |
Free Cash Flow Margin | 33.50% | 37.93% | -0.72% | -13.68% | -3.15% | -3.29% | Upgrade |
Free Cash Flow Per Share | 1.19 | 1.36 | -0.03 | -0.67 | -0.14 | -0.13 | Upgrade |
Cash Interest Paid | 159.9 | 159.9 | 249.83 | - | - | - | Upgrade |
Cash Income Tax Paid | 87.17 | 132.57 | 62.14 | -270.8 | -129.34 | 90.52 | Upgrade |
Levered Free Cash Flow | 2,036 | 1,753 | 183.13 | -1,494 | -435.43 | -254.76 | Upgrade |
Unlevered Free Cash Flow | 2,277 | 1,842 | 322.64 | -1,347 | -309.41 | -99.93 | Upgrade |
Change in Working Capital | 823.68 | 1,222 | 361.44 | -2,313 | -1,127 | -861.99 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.